WO2000061557A1 - Derives de 4-hydroxypiperidine ayant un effet anti-arythmique - Google Patents
Derives de 4-hydroxypiperidine ayant un effet anti-arythmique Download PDFInfo
- Publication number
- WO2000061557A1 WO2000061557A1 PCT/JP2000/002331 JP0002331W WO0061557A1 WO 2000061557 A1 WO2000061557 A1 WO 2000061557A1 JP 0002331 W JP0002331 W JP 0002331W WO 0061557 A1 WO0061557 A1 WO 0061557A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ethyl
- methyl
- iso
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a novel 4-hydroxypiperidine derivative, a method for producing the same, a pharmaceutical composition containing at least one of the derivatives as an active ingredient, and particularly to an orally administrable antiarrhythmic agent.
- the heart beats regularly with the orderly transmission of excitement that began in the sinus node.
- Arrhythmias occur when abnormal excitation or conduction occurs in the heart. Therefore, the mechanisms of arrhythmia are classified into three groups: 1 abnormal stimulus generation, 2 abnormal excitation conduction, and 3 a combination of abnormal stimulus generation and abnormal excitation conduction.
- Vaughan Williams Ia 11ams
- Singh Singh
- House Virth House Virth classified antiarrhythmic drugs into four groups based on their effects in the 1970s. The first half. Since then, it has been used as a standard for antiarrhythmic drug classification as the Vaughan an Wi11ams classification.
- This classification method is distinguished by its succinct representation of the pharmacological properties of various drugs and has been used by many clinicians. In this classification method, antiarrhythmic drugs are roughly divided into four groups, ie, groups I to IV.
- Antiarrhythmic drugs classified into Group I are drugs whose main function is to block sodium channels. They reduce the maximum rise rate of action potential phase 0 depolarization and decrease the conduction rate. In addition, they are subdivided into Ia, Ib, and Ic depending on the effect on the action potential duration.
- a special feature of group I drugs is that sodium sodium blockade decreases intracellular sodium, so that the sodium Z-calcium exchange mechanism acts to reduce intracellular calcium and decrease myocardial contractility. This is one of the important side effects, as well as the proarrhythmic effect directly related to conduction suppression by the sodium channel blocking effect.
- Antiarrhythmic drugs classified into Group II are drugs with a main function of blocking 3 receptors.
- Catecholamine stimulates the cardiomyocyte / 3 (i3,) receptor to stimulate adenylate. Activates clase, increases cyclic AMP production, and increases inward calcium current. As a result, it enhances physiological abilities such as sinus node and abnormal abilities in pathological myocardium. It also shortens the action potential duration by activating various ion channels involved in repolarization.
- Group II antiarrhythmic drugs are effective against arrhythmias involving sympathetic nerves by antagonizing catecholamine action. However, due to their 3 receptor blocking effects, side effects such as suppression of cardiac function may be a concern.
- Anti-arrhythmic drugs classified as group I I I are defined as drugs that delay repolarization and have a prolonged action potential duration. Treats arrhythmias by extending the duration of the action potential and prolonging the refractory period. Recent research has shown that the primary effects of these drugs are potassium channel blocking, and potassium channel blockers and Group II drugs are now being used as synonyms. Class I drugs, unlike Group I drugs, have the advantage of not suppressing myocardial contractility. While I
- torsadopoint torsadesdepointees
- Antiarrhythmic drugs classified into the IV group are defined as drugs whose main function is to block calcium channels. It is used for the treatment of arrhythmias caused by the hyperactivity of the sinus node and arrhythmias involving the atrioventricular node.
- verabamil has the disadvantage that it weakens the contractile force of the myocardium.
- Group II and IV drugs are effective only for limited arrhythmias. Therefore, the emergence of a new type of antiarrhythmic drug that is highly safe and avoids the drawbacks of conventional antiarrhythmic drugs classified into Group I to Group IV drugs is desired.
- the normally observed sodium current is rapidly activated by stimulation (depolarization) and then rapidly inactivated, and the observed current is a transient inward current.
- Group I drugs suppress this transient sodium current, reduce the maximum rate of onset of action potential phase 0 depolarization, and decrease the conduction rate.
- some of the sodium currents are slowly or hardly inactivated, and are thought to be involved in the control of excitability of nerve cells and cardiomyocytes in physiological conditions. This current is called the persistent sodium current. It has also been suggested that this current is involved in abnormal excitation of nerve cells (eg, during epileptic seizures ⁇ ischemia) and in pathological states of cardiomyocytes (eg, occurrence of arrhythmia) (Segal et al.
- Lidocaine and quinidine have been reported as compounds that inhibit the sustained sodium current in the heart muscle (Ju YK, et al., “British Journal of Pharmacolology”). 107, 311-316, 1992), these compounds are class I drugs, which suppress not only persistent sodium current but also transient sodium current, and have no specificity.
- phenytoin has been reported to suppress this current (Segal et al.), Journal of Neurological Neurology (Journal of Neurop hy siology) 77, 3021 -Pp. 3034, 1997), and phenytoin also does not have high specificity for sustained sodium currents as classified as a group I antiarrhythmic drug.
- JP-A-50-36471 As a 4-hydroxypiperidine derivative, a compound having an analgesic activity is reported in JP-A-50-36471, but there is no disclosure about an antiarrhythmic effect such as the compound of the present invention.
- a piperidine derivative a compound having an antiarrhythmic action is disclosed in JP-A-59-225161, but the structure of the compound is different from that of the compound of the present invention. It is concerned that there will be any side effects that affect the environment. It has not been developed as a pharmaceutical.
- Japanese Patent Application Laid-Open No. 6-50093 discloses a 4-substituted piperidine derivative having a calcium-blocking effect as a cerebral protective agent, but does not disclose any antiarrhythmic effect such as the compound of the present invention. There is no.
- drug development requires not only the desired pharmacological activity but also long-term safety.
- it is required to meet strict criteria in various aspects such as absorption, distribution, metabolism, and excretion.
- drug interactions desensitization or tolerance, absorption in the gastrointestinal tract upon oral administration, translocation rate into the small intestine, absorption rate and first-pass effect, organ barrier, protein binding, induction of drug metabolizing enzymes, excretion pathways and body clearance
- various issues to be studied are required in terms of application method (application site, method, purpose), etc., and it is difficult to find one that satisfies these requirements.
- Antiarrhythmic drugs are also required to avoid the above-mentioned problems such as proarrhythmic action, cardiac function suppression action, torsadesdepointes associated with prolonged QT time, and increased sudden death. It is.
- An object of the present invention is to provide a highly safe novel compound having an antiarrhythmic effect and having few side effects.
- Another object of the present invention is to provide a method for producing them, a medicine and a pharmaceutical composition containing them.
- problems such as proarrhythmic action, cardiac function suppressing action, torsades depointes associated with prolonged QT time, and increase in sudden death of the conventional drug. Overcoming at least one or more of these in that it does not affect the excitation conduction or action potential duration of the normal myocardium, and thus has little proarrhythmic action or cardiac function suppression, or the prevention of sudden death.
- An object of the present invention is to provide an orally administrable drug, particularly an antiarrhythmic agent, for mammals including humans.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems and obtain a drug having excellent antiarrhythmic activity and high safety.
- a novel 4-hydroxypiperidine derivative and The salt has an inhibitory effect on the contracture of isolated myocardium by veratrine, is orally effective in an ischemia-reperfusion arrhythmia model, does not affect normal myocardial activity, and has fewer side effects and is safe
- the present invention was found to be highly efficient, and the present invention was completed.
- a first aspect of the present invention is a compound represented by the following formula (I):
- A is substituted represents a phenyl group, a naphthyl group or a monocyclic aromatic heterocycle RR 2; the RR 2 are each independently a hydrogen atom, a halogen atom, triflate Oromechiru group, Shiano group, a lower alkoxy
- A is, R 1, it by R 2 is been phenyl group or a thienyl group substituted rather preferably, R 1, R 2 is preferably Ri good a substituted phenyl group or an unsubstituted thienyl group. Furthermore, A is a substituted phenyl group RR 2, binding position of R 1 is - X - is preferably a para (position 4) with respect to.
- RR 2 is a hydrogen atom, a halogen atom, a trifluoromethyl group, Preferably an ano group, a lower alkoxycarbonyl group, a lower alkanoylamino group optionally substituted by a fluorine atom, a lower alkoxy group, a lower alkyl group, a trifluoromethoxy group, a nitro group, or a lower alkylthio group; More preferably, they are an atom, a halogen atom, a trifluoromethyl group, a cyano group, a lower alkoxycarbonyl group, and a trifluoromethoxy group.
- R 1 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, a lower alkoxycarbonyl group, a lower alkanoylamino group which may be substituted by a fluorine atom, a lower alkoxy group, A lower alkyl group, a trifluoromethoxy group, a nitro group or a lower alkylthio group, wherein R 2 is preferably a hydrogen atom or a halogen atom, and R 1 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, A lower alkoxycarbonyl group or a trifluoromethoxy group, and R 2 is more preferably a hydrogen atom or a halogen atom.
- R 3 is preferably a hydrogen atom.
- R 4 is preferably a lower alkyl group or a lower alkyl group, more preferably a lower alkyl group.
- R 5 is preferably a lower alkoxy group, a lower alkyl group or a phenoxy group, more preferably an alkoxy group having 2 to 6 carbon atoms, and a straight-chain or branched chain having 2 to 4 carbon atoms. More preferably, it is an alkoxy group.
- R 6 is preferably a hydrogen atom, a halogen atom, an optionally protected hydroxyl group or a lower alkyl group optionally substituted with an optionally protected hydroxyl group, more preferably a hydrogen atom .
- R 5 is preferably an alkoxy group having 2 to 6 carbon atoms
- R 6 is preferably a hydrogen atom
- R 5 is a straight-chain or 2 to 4 carbon atoms. More preferably, it is a branched alkoxy group
- R 6 is a hydrogen atom.
- R 5 is para position (position 4) with respect to 1 NR 4 —.
- X is preferably a single bond or a group: one CH (OH) —, more preferably a single bond.
- Y is an alkylene group having 1 or 2 carbon atoms or preferably represents a substituted benzylidene group R 1,, and more preferably Benjiride emissions group substituted with a methylene group or R 1.
- Y is preferably a danyl group when A is a phenyl group and forms a 5- or 6-membered ring together with X and a carbon atom on the benzene ring.
- Z is preferably a single bond or a methylene group which may be substituted with a hydroxyl group, and more preferably a methylene group.
- R 7 and R 8 are preferably each a hydrogen atom.
- the bonding position of R 5 is para (4 position) with respect to —NR 4 —
- R 7 and R 8 are each a hydrogen atom
- X is a single bond
- Y is Is preferably an alkylene group having 1 or 2 carbon atoms, or a benzylidene group substituted with R 1 .
- A is a phenyl group or a phenyl group substituted with RR 2
- R 4 is a lower alkyl group
- Z is a single bond or a methylene group.
- R 1 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, a lower alkoxycarbonyl group or a trifluoromethoxy group
- R 2 is a hydrogen atom or a halogen atom
- R 3 is a hydrogen atom
- R 5 is an alkoxy group having 2 to 6 carbon atoms
- R 6 is a hydrogen atom
- Y is a methylene group or a benzylidene group substituted by R 1 .
- the compound of the present invention is a compound of the formula (I) or a salt thereof.
- Specific examples of compounds having a more preferable combination of substituents are as follows.
- A is a phenyl group substituted with RR 2 or an unsubstituted phenyl group;
- R 1 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, a lower alkoxycarbonyl group or a trifluoromethyl group;
- R 2 is a hydrogen atom or a halogen atom;
- R 3 is a hydrogen atom:
- R 4 is a methyl group;
- R 5 is a straight or branched chain having 2 to 4 carbon atoms.
- R 6 is a hydrogen atom
- R 7 is a hydrogen atom
- R 8 is a hydrogen atom
- Y is a methylene group or a benzylidene group substituted with R 1 ; and a compound wherein Z is a methylene group. Or its salt.
- equation (I) is also written as equation (II),
- a ' represents a phenyl group substituted by RR 2 or an unsubstituted phenyl group, and — O (C 2-4 A 1 k) represents a straight-chain or branched-chain having 2 to 4 carbon atoms. Represents an alkoxy group, and Ya represents a methylene group or a benzylidene group substituted by R 1. )
- a second aspect of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- a third aspect of the present invention is an antiarrhythmic agent, comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. It is also an orally administrable antiarrhythmic agent.
- a fourth aspect of the present invention is a compound represented by the following formula (I) -a, wherein R 7 and R 8 in the formula (I) are both hydrogen atoms.
- ⁇ represents an alkyl halide
- ⁇ represents an alkyl halide
- it is reacted in the presence or absence of a base, or when Y'-Q together form an aldehyde or ketone, in the presence or absence of an acid catalyst
- R 7 and R 8 are both hydrogen atoms; Is the following formula (I)
- A, R 3 , R 4 , R 5 , R 6 , X, and Y have the same meanings as described above, and Z ′ represents a lower alkyl group, a lower alkoxy group, or an optionally protected hydroxyl group.
- Z ′ represents a lower alkyl group, a lower alkoxy group, or an optionally protected hydroxyl group.
- a methylene group which may be substituted with a group arbitrarily selected from the group consisting of the following: (c) or (d) Method using.
- R 4 ′, R 5 , R 6 , and Z ′ have the same meanings as described above, and W represents a hydrogen atom or a halogen atom).
- the compound represented by is reacted in the presence or absence of a base or Y'-Q is The reaction is carried out under reducing conditions in the presence or absence of an acid catalyst when the compound represents a aldehyde or a ketone, or after the reaction using a condensing agent when --Y '-Q together form a carboxylic acid, followed by reduction. Performing a reaction.
- the compound of the present invention is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.
- A represents a phenyl group / naphthyl group or a monocyclic aromatic heterocyclic ring substituted by RR 2 ;
- R 1 and R 2 each independently represent a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group
- R 7 and R 8 each independently represent a hydrogen atom or a lower alkyl group. However, this excludes the case where R 5 and R 6 are both hydrogen atoms. ).
- “Monocyclic aromatic heterocycle” means a 5-membered or 6-membered aromatic ring having one or two heteroatoms, such as a pyrrolyl group, a furyl group, a chenyl group, an imidazolyl group, Oxazolyl group, thiazolyl group, pyridyl group, pyrimidinyl group and the like.
- halogen atom includes a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.
- “Lower” means a straight, branched or cyclic carbon chain having any one of 1 to 6 carbon atoms, unless otherwise specified. Accordingly, the “lower alkyl group” includes, for example, methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl , 3-pentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, iso-hexyl, 1-methylpentyl, 2 —Methylpentyl group, 3-methylpentyl group, 1,1-dimethylbutyl group, 1,2-dimethylbutyl group, 2,2-dimethylbutyl group, 1,3-dimethylbutyl group, 2,3-dimethylbutyl group, 3 1,3
- “Lower alkyl group mono-substituted with a hydroxyl group” means any lower alkyl group described above. Means a group in which one hydrogen atom has been replaced with a hydroxyl group. Specifically, for example, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a 2-hydroxypropyl group, a 3-hydroxy Propyl group, 1-hydroxy-1-methylpropyl group, 1-hydroxybutyl group, 2-hydroxybutyl group, 3-hydroxybutyl group, 4-hydroxybutyl group, 1-hydroxy_1-methylbutyl group, 1-hydroxypentyl group, 2-hydroxypentyl, 3-hydroxypentyl, 4-hydroxypentyl, 5-hydroxypentyl, 1-hydroxy-1-methylpentyl, 1-hydroxyhexyl, 2-hydroxyhexyl, 3 —Hydroxyhexyl, 4-hydroxyhex
- “Lower alkoxycarbonyl” includes methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso-propoxycarbonyl, butoxycarbonyl, iso-butoxycarbonyl, sec-butoxycarbonyl, tert-carbonyl.
- amino group optionally mono- or di-substituted with a lower alkyl group means an amino group in which one or two hydrogen atoms of an amino group may be substituted with the above “lower alkyl group”. I do. Specifically, amino group, methylamino group, ethylamino group, propylamino group, iso-propylamino group, butylamino group, iso-butylamino group, pentylamino group, iso-pentylamino group, Silamino group, iso-hexylamino group, dimethylamino group, getylamino group, dipropylamino group, G-iso-propylamino group, dibutylamino group, dipentylamino group, ethylmethylamino group, methylpropylamino group, ethylproble Examples include an amino group, a butylmethylamino group, a butyleth
- Examples of the "lower alkylamino group optionally substituted by a fluorine atom” include a formylamino group, an acetylamino group, a monofluoroacetylamino group, a difluoroacetylamino group, and a trifluoroacetylamino group.
- propionylamino 2—fluoropropionylamino
- 3 fluoropropionylamino, 2,2-difluoropropionylamino, 2,3-difluoropropionylamino , 3,3,3-trifluoropropionylamino group, 2,2,3,3-tetrafluoropropionylamino group, pentafluorofluoropropionylamino group, petyrylamino group, iso-butyrylamino group
- Examples include a norylamino group, an iso-valerylamino group, a vivaloylamino group, and a hexanoylamino group.
- Examples of the “lower alkoxy group” include a methoxy group, an ethoxy group, a propoxy group, an iso-propoxy group, a butoxy group, an iso-butoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxy group, an iso-pentyloxy group, 3-pentyloxy, tert-pentyloxy, neopentyloxy, 2-methylbutoxy, 1,2-dimethylpropoxy, 1-ethylpropoxy, hexyloxy, cyclopropyloxy, cyclobutyloxy Xy, cyclopentyloxy, cyclohexyloxy, cyclopropylmethyloxy, 1-cyclopropylethyloxy, 2-cyclopropylethyloxy, cyclobutylmethyloxy, 2- And cyclobutylethyloxy and cyclopentylmethyloxy. That.
- lower alkoxy group substituted by 1 with a hydroxyl group means a group having one or more hydrogen atoms except for the 1-position of the above lower alkoxy group having 2 to 6 carbon atoms, which is substituted with a hydroxyl group.
- the lower alkyl group optionally mono- or di-substituted is a molybmoyl group means that one or two hydrogen atoms on the nitrogen atom of the molybmoyl group are substituted with the above “lower alkyl group”. Means a good rubamoyl group.
- carbamoyl methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, iso-propyl carbamoyl, cyclopropylcarbamoyl, butylcarbamoyl, iso-butylcarbamoyl, pentylcarbamoyl Group, iso-pentylcarbamoyl group, hexylcarbamoyl group, iso-hexylcarbamoyl group, dimethylcarbamoyl group, getylcarbamoyl group, dipropyl-powered rubamoyl group, di-iso-propyl-powered rubamoyl group, dibutyl carbamoyl group, dipentylcarbamoyl group, Ethylmethylcarbamoyl group, methylpropyl-lubamoyl group, ethylpropyl-
- lower alkanoyl group examples include formyl group, acetyl group, propionyl group, butyryl group, iso-butyryl group, valeryl group, iso-valeryl group, bivaloyl group, hexanoyl group and the like.
- “Lower alkylthio” includes, for example, methylthio, ethylthio, propylthio, iso-propylthio, butylthio, iso-butylthio, sec-butylthio, tert-butylthio, pentylthio, iso-ethylthio and the like.
- Tert-pentylthio group neopentylthio group, 2-methylbutylthio group, 1,2-dimethylpropylthio group, 1-ethylpropylthio group, hexylthio group, cyclopropylthio group, cyclobutylthio group, cyclopentylthio group Group, cyclohexylthio group, cyclopropylmethylthio group, 1-cyclopropylethylthio group, 2-cyclopropylethylthio group, cyclobutylmethylthio group, Examples thereof include a 2-cyclobutylethylthio group and a cyclopentylmethylthio group.
- lower alkylsulfinyl group examples include a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an iso-propylsulfinyl group, a butylsulfinyl group, an iso-butylsulfinyl group, a sec-butylsulfinyl group, a tert-butylsulfinyl group , Pentylsulfinyl, iso-pentylsulfinyl, tert-pentylsulfinyl, neopentylsulfinyl, 2-methylbutylsulfinyl, 1,2-dimethylpropylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl , Cyclopropylsulfinyl,
- lower alkylsulfonyl group examples include a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an iso-propylsulfonyl group, a butylsulfonyl group, an iso-butylsulfonyl group, a sec-butylsulfonyl group, a tert-butylsulfonyl group, Pentylsulfonyl, iso-pentylsulfonyl, tert-pentylsulfonyl, neopentylsulfonyl, 2-methylbutylsulfonyl, 1,2-dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl , Cyclopropylsulfonyl, cycl
- “Sulfamoyl group optionally mono- or di-substituted with a lower alkyl group” means that one or two hydrogen atoms on the nitrogen atom of the sulfamoyl group are substituted with the above “lower alkyl group”. Means a good sulfamoyl group.
- sulfamoyl group methylsulfamoyl group, ethylsulfamoyl Group, propylsulfamoyl, iso-propylsulfamoyl, cyclopropylsulfamoyl, butylsulfamoyl, iso-butylsulfamoyl, pentylsulfamoyl, iso-pentylsulfamoyl Group, hexylsulfamoyl, iso-hexylsulfamoyl, dimethylsulfamoyl, getylsulfamoyl, dipropylsulfamoyl, di-iso-propylsulfamoyl, dibutylsulfamoyl Group, dipentylsulfamoyl group, ethylmethylsulfamoyl group, methylpropylsulfamo
- alkylenedioxy group examples include a methylenedioxy group, an ethylenedioxy group and the like.
- “Lower alkenyloxy group” means a group in which one of carbon-carbon bonds of a lower alkoxy group having 3 to 6 carbon atoms is a double bond and the position is not the 1-position.
- 2-propenyloxy group 1-methyl-2-propenyloxy group, 2-methyl-2-propenyloxy group, 1,1-dimethyl-2-propenyloxy group, 1 1,2-Dimethyl-2-propenyloxy, 1,1,2-trimethyl-2-propenyloxy, 2-butenyloxy, 1-methyl-2-butenyloxy, 2-methyl-2-butenyloxy , 3-methyl-2-butenyloxy, 3-butenyloxy, 1-methyl-3-butenyloxy, 21-pentenyloxy, 3-pentenyloxy, 4-pentenyloxy, 2-cyclopentenyloxy, 2- Hexenyloxy, 3-hexenyloxy, 4-hexenyloxy, 5-hexenyloxy, 2-cyclohexeny
- “Lower alkylene group or lower alkylidene group” means an alkylene group or an alkylidene group having 1 to 6 carbon atoms, and includes a methylene group, an ethylene group, a methylmethylene group, a trimethylene group, a dimethylmethylene group, a tetramethylene group, Tiltrimethylene group, ethylethylene group, dimethylethylene group, ethylmethylmethylene group, pentamethylene group, methyltetramethylene group, dimethyltrimethylene group, trimethylethylene group, dimethylmethylene group, hexamethylene group, methyl Examples thereof include a methylene group and a dimethyltetramethylene group, and include a linear or branched one.
- Examples of the protecting group of the “optionally protected hydroxyl group” in the present specification include an alkyl-based protecting group such as a methyl group, a tert-butyl group, a benzyl group, a trityl group, and a methoxymethyl group, a trimethylsilyl group and a tert-butyl group.
- Examples include silyl protecting groups such as dimethylsilyl group, etc., acyl protecting groups such as formyl group, acetyl group and benzoyl group, and carbonate protecting groups such as methoxycarbonyl group and benzyloxycarbonyl group.
- Examples of the protecting group of the “optionally protected carboxyl group” in the present specification include alkyl ester protecting groups such as methyl group, ethyl group, tert-butyl group, benzyl group, diphenylmethyl group, and trityl group.
- Examples include silyl ester-based protecting groups such as a trimethylsilyl group and a tert-butyldimethylsilyl group.
- A is preferably a phenyl group, a naphthyl group, a furyl group, a phenyl group or a pyridyl group, more preferably a phenyl group or a phenyl group, and further preferably a phenyl group.
- R 1 and R 2 are a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a cyano group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an iso-propoxycarbonyl group, and a dimethylamino group, respectively.
- R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a cyano group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an iso group.
- R 2 is a hydrogen atom Or a fluorine atom
- R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a cyano group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an iso-propoxycarbonyl a group or a triflate Ruo b methoxy group, if R 2 is a hydrogen atom clause Oh fluorine atom It is more preferable.
- R 3 is preferably a hydrogen atom or a methyl group, and more preferably a hydrogen atom.
- R 4 is preferably a hydrogen atom, a methyl group, an ethyl group, an iso-propyl group or an acetyl group, more preferably a methyl group, an ethyl group, an iso-propyl group or an acetyl group, and a methyl group More preferably, it is a methyl group or an iso-propoxy group.
- R 5 is methoxy, ethoxy, propoxy, iso_propoxy, butoxy, iso-butoxy, cyclobutoxy, cyclopropylmethyloxy, 2-cyclopropylethyloxy, pentyloxy Group, 3-pentyloxy group, iso-pentyloxy group, 2-methyl-2-butoxy group, cyclohexyloxy group, 3-butenyloxy group, 3-hydroxybutyloxy group, 4-hydroxybutyloxy group , Propyl and phenoxy groups; ethoxy, propoxy, iso-propoxy, butoxy, iso-butoxy, cyclobutoxy, cyclopropylmethyloxy, 2-cyclopropyl More preferably, it is an ethyloxy group, a pentyloxy group, a 3-pentyloxy group, an iso-pentyloxy group, a 2-methyl-2-butoxy group, or a cyclohexyloxy group, and an ethoxy group,
- R 6 is preferably a hydrogen atom, a fluorine atom, a hydroxyl group or a hydroxymethyl group, and more preferably a hydrogen atom.
- R 5 is an ethoxy group, a propoxy group, an iso-propoxy group, a butoxy group, an iso-butoxy group, a cyclobutoxy group, a cyclobutylpyrmethyloxy group, a 2-cyclopropylethyloxy group
- R 6 is preferably a hydrogen atom
- R s is an ethoxy group, a propoxy group, More preferably, they are an iso-propoxy group, a butoxy group, or an iso-butoxy group
- R 6 is a hydrogen atom.
- the bonding position of R 5 is at the para position (position 4) with respect to —NR 4 —.
- X is preferably a single bond, a group: one CH (OH) 1, an oxygen atom or a carbonyl group, more preferably a single bond or a group: _CH (OH) 1, preferably a single bond More preferred.
- Y is preferably a methylene group, an ethylene group, a methylmethylene group, a trimethylene group, a benzylidene group or a 4′-fluorobenzylidene group, and is preferably a methylene group, an ethylene group, a benzylidene group or a 4′-fluorobenzyl group. More preferably, it is a methylene group, a benzylidene group or a 4′-fluorobenzylidene group.
- Y preferably forms an indanyl group when A is a phenyl group and forms a 5- or 6-membered ring together with X and a carbon atom on the benzene ring.
- Z is preferably a single bond or a methylene group which may be substituted with a methoxy group or a hydroxyl group, and more preferably a methylene group.
- R 7 and R 8 are preferably each a hydrogen atom.
- A is a substituted been phenyl group, naphthyl group, furyl group, a thienyl group or a pyridyl group RR 2; RR 2 forces it Hydrogen, fluorine, chlorine, bromine, trifluoromethyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso-propoxycarbonyl, dimethylamino, trifluoro Acetylamino, hydroxyl, methoxy, iso-propoxy, methyl, iso-propyl, trifluoromethoxy, nitro, phenyl, phenoxy, carboxyl, carbamoyl, dimethylcarbamoyl, Acetyl, methylthio, methylsulfinyl, methylsulfonyl, or sulfamoyl; or R 1 and R 2 together form a methylenedioxy group; R 3 is a hydrogen atom
- A is a phenyl or phenyl group substituted with RR 2 ;
- R 1 and R 2 are each a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl group, a cyano group, or a methoxycarbonyl group;
- R 3 is a hydrogen atom or a methyl group
- R 4 is a
- A is a phenyl group, a naphthyl group, a furyl group, a phenyl group or a pyridyl group substituted by RR 2 ;
- R 1 is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a trifluoromethyl
- R 2 is a hydrogen atom or a fluorine atom;
- R 3 is a hydrogen atom; a cyano group, a cyano group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an iso-propoxycarbonyl group, or a trifluoromethoxy group;
- R 4 is a hydrogen atom, a methyl group, an ethyl group, an iso-propyl group or an acetyl group;
- R 5 is an ethoxy group, a propoxy group, an iso-propoxy group, a
- the compound of the present invention is a compound of the formula (I) or a salt thereof.
- Specific examples of compounds having a more preferable combination of substituents are as follows.
- A is a phenyl group substituted with RR 2 or an unsubstituted phenyl group; and R 1 is a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, a lower alkoxycarbonyl group or a trifluoro group.
- R 2 is a hydrogen atom or a halogen atom;
- R 3 is a hydrogen atom;
- R 4 is a methyl group;
- R 5 is a straight or branched chain having 2 to 4 carbon atoms.
- R 6 is a hydrogen atom
- R 7 is a hydrogen atom
- R 8 is a hydrogen atom
- X is an alkoxy group having a bonding position para to (NR 4 ) with respect to —NR 4 —.
- Y is a methylene group or a benzylidene group substituted with R 1 ; and a compound or a salt thereof, wherein Z is a methylene group.
- equation (I) is also represented as equation ( ⁇ ).
- a ′ represents a phenyl group substituted by RR 2 or an unsubstituted phenyl group
- one O (C 2 _ 4 A 1 k) represents a straight or branched chain having 2 to 4 carbon atoms.
- Ya represents a methylene group or a benzylidene group substituted by R 1.
- Preferred examples of the compound of the formula (I) include the following:
- the compound of the present invention may have an asymmetric carbon atom, and may be any optically active or inactive stereoisomer (enantiomer, diastereomer or the like), a mixture of various isomers such as geometric isomers or tautomers, or a single isomer. Those separated are included in the present invention.
- stereoisomers can be isolated and purified by a person skilled in the art by ordinary techniques through optical resolution or asymmetric synthesis using preferential crystallization-column chromatography.
- the compound (I) of the present invention may form an acid addition salt. Further, depending on the type of the substituent, a salt with a base may be formed.
- the salt is not particularly limited as long as it is a pharmaceutically acceptable salt, and specific examples thereof include mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic carboxylic acids such as acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, formic acid, malic acid, tartaric acid, citric acid, and mandelic acid, methanesulfonic acid, and sulfonic acid Acid addition salts with organic sulfonic acids such as benzenesulfonic acid, p-toluenesulfonic acid, and 2-hydroxyethanesulfonic acid; acidic amino acids such as aspartic acid and glutamic acid; sodium, potassium, magnesium, calcium, aluminum Alkali metal or alkaline earth metal bases such as methylamine, ethylamine, ethanolamine, Examples thereof include salts with organic bases such as gin, lysine, arginine, and orditin, and ammonium salts.
- organic bases such as gin, lysine, arginine, and orditin, and ammoni
- salts can be obtained in a conventional manner, for example, by mixing a solution containing an equivalent amount of the compound of the present invention and a desired acid or base, and collecting the desired salt by filtration or distilling off the solvent.
- the compound of the present invention or a salt thereof may form a solvate with a solvent such as water, ethanol, and glycerol.
- the salt of the compound of the present invention includes a monosalt, a disalt or a trisalt.
- the compound of the present invention may simultaneously form both an acid addition salt and a salt with a base, depending on the substituent on the side chain.
- the present invention also includes hydrates of compound (I), various pharmaceutically acceptable solvates and polymorphs thereof.
- the present invention is, of course, not limited to the compounds described in the Examples below, but may be compounds of the formula (I) or pharmaceuticals. It is intended to include all the salts which are acceptable.
- the compound of the present invention represented by the formula (I) or a salt thereof can be prepared from a compound known in the literature or easily prepared from a commercially available compound represented by the formula (III) (wherein R 4 ′ and R 5 ′) , R 6 ′ represents the same meaning as described above), formula ( ⁇ ′) (wherein R 4 ′, R 5 , and R 6 represent the same meaning as described above), formula (IV) (where A, R 3 , X, Y ′, and ⁇ represent the same meaning as described above), Formula (V) (wherein R 3 , P, and Z represent the same meaning as described above), Formula (XI), Formula (XII) ), Formula (XIII), formula (XIV) (wherein A, R 3 , R 7 , X, Y ′, and ⁇ represent the same meaning as described above), formula (XV) (where R 3 , R 7 , P and Z represent the same meaning as described above), formula (XVIII) (where A, R 3 , R 7
- the compound represented by the formula (I) —a or a salt thereof is obtained by reacting the compound represented by the formula (III) and the compound represented by the formula (IV) or the compound represented by the formula (V) ⁇ It can be manufactured according to each manufacturing process,
- Reaction formula 1 ⁇ Step 1> A compound represented by the formula (III) and a compound represented by the formula (IV) are combined with 1-ethyl-3- (3-dimethylaminopropyl) carbopimide hydrochloride (water-soluble ruposimide hydrochloride, Using a condensing agent such as WSC ⁇ HC 1) ⁇ dicyclohexylcarposimide (DCC), halogen solvents such as methylene chloride and chloroform, ether solvents such as dimethyl ether and tetrahydrofuran, and hydrocarbons such as benzene and hexane.
- a condensing agent such as WSC ⁇ HC 1
- DCC dicyclohexylcarposimide
- halogen solvents such as methylene chloride and chloroform
- ether solvents such as dimethyl ether and tetrahydrofuran
- hydrocarbons such as benzene and hexane.
- the compound represented by the formula (VI) can be produced by reacting at a temperature at which the reaction mixture is refluxed from 0 in a solvent that does not participate in the reaction, such as a system solvent, a polar solvent such as dimethylformamide and dimethylsulfoxide. it can.
- a solvent that does not participate in the reaction such as a system solvent, a polar solvent such as dimethylformamide and dimethylsulfoxide. it can.
- This reaction is carried out using a dehydrating agent such as phosphorus oxychloride or the like, in the presence of a base such as pyridine or triethylamine, a halogen-based solvent such as methylene chloride or chloroform, ethyl ether or an ether-based solvent such as tetrahydrofuran, or benzene.
- a base such as pyridine or triethylamine
- a halogen-based solvent such as methylene chloride or chloroform
- ethyl ether or an ether-based solvent such as tetrahydrofuran, or benzene.
- the reaction can also be carried out in a solvent that does not participate in the reaction, such as a hydrocarbon-based solvent such as xane, at a temperature at which the reaction mixture refluxes from 120.
- the compound represented by the formula (VI) is obtained by converting the compound represented by the formula (IV) into an acid chloride using, for example, thionyl chloride, an organic base such as triethylamine / pyridine, and an inorganic base such as potassium carbonate.
- a base in a solvent such as a halogen-based solvent such as methylene chloride or chloroform, an ether-based solvent such as getyl ether ⁇ ⁇ ⁇ tetrahydrofuran, or a hydrocarbon-based solvent such as benzene or hexane, or a base such as pyridine or triethylamine. It can also be produced by reacting the compound with the compound represented by the formula (III) at a temperature at which the reaction mixture refluxes in a neutral solvent.
- the compound represented by the formula (VI) can also be produced according to the following ⁇ Step 2>, Step 3> and Step 4>.
- Step 2> A compound represented by the formula (VII) (wherein R 3 , R 4 ′, R 5 ′, R 6 ′, P and Z represent the same meaning as described above) is represented by the formula (III) From the compound represented by the formula (V) and the compound represented by the formula (V).
- Protecting groups P include John 'Willie' and 'Sands (John Wileyand
- protecting groups such as benzyl, trityl, methoxymethyl and other alkyl-based protecting groups, tert-butoxycarbonyl group 'benzyl And a protecting group such as a sulfamate group such as an oxycarbonyl group.
- the compound represented by the formula (VIII) can be produced by deprotecting piperidine at position 1 of the compound represented by the formula (VI I).
- Deprotection of the compound represented by formula (VII) at the 1-position of piperidine is carried out according to the method described in Protective Groups in Organic 'Synthesis (Third Edition). , 1999, can be carried out according to the method described in the review.
- the protecting group (P in the formula) is a benzyl group, a benzyloxycarbonyl group, or the like
- an alcoholic solvent such as methanol or ethanol, ethyl acetate, acetic acid, water, or the like, using palladium monocarbon, platinum oxide, or the like as a catalyst.
- the compound represented by the formula (VIII) can be produced by performing deprotection in a solvent under a hydrogen atmosphere or in the presence of ammonium formate at a temperature at which the reaction mixture refluxes from 0.
- the protecting group (P in the formula) is a tert-butoxycarbonyl group or the like
- an acid such as trifluoroacetic acid or hydrochloric acid is used in the presence or absence of anisole at a temperature from 0 to the temperature at which the reaction mixture is refluxed.
- Step 4> The reaction between the compound represented by the formula (VIII) and the compound represented by the formula (IX) can be carried out by the following method depending on the type of —Y′—Q.
- the compound represented by the formula (VI) can be produced by reacting in a solvent that does not participate in the reaction, such as a polar solvent such as de-dimethylsulfoxide, at a temperature from 0 to the reflux temperature of the reaction mixture. At this time, use sodium iodide or the like as a catalyst. Can also be.
- the compound represented by the formula (VI II) and the compound represented by the formula (IX) are converted to an aromatic hydrocarbon such as toluene and benzene.
- a suitable reducing agent in the presence or absence of an acid catalyst such as acetic acid in a solvent such as a system solvent, a halogen-based solvent such as methylene chloride or chloroform, or an alcohol-based solvent such as methanol or ethanol.
- an acid catalyst such as acetic acid
- a solvent such as a system solvent, a halogen-based solvent such as methylene chloride or chloroform, or an alcohol-based solvent such as methanol or ethanol.
- any reducing agent capable of reducing an imino group to an amino group can be used, and among them, sodium triacetoxyborohydride, sodium borohydride, lithium borohydride, di-iso-butylaluminum hydride is preferable.
- a reducing agent such as sodium cyanoborohydride is preferable, and the reaction can be carried out in a time period from 1 to 78 hours at room temperature, preferably at room temperature, more specifically from 3 hours to 12 hours. .
- Step 5 Reduction of the compound represented by the formula (VI) with borane complex salts such as lithium aluminum hydride, di-iso-butylaluminum hydride, borane-methyl sulfide complex, porane-tetrahydrofuran complex salt, etc.
- the reaction is carried out at a temperature at which the reaction mixture refluxes from o in a solvent that does not participate in the reaction, such as an ether solvent such as getyl ether and tetrahydrofuran, and an aromatic hydrocarbon solvent such as toluene and benzene.
- a solvent that does not participate in the reaction such as an ether solvent such as getyl ether and tetrahydrofuran, and an aromatic hydrocarbon solvent such as toluene and benzene.
- Y ′ in the compound represented by the formula (VI) represents an alkylenecarbonyl group or a carbonyl group
- the compound is simultaneously reduced under the reaction conditions to obtain a compound in which Y is a corresponding lower alkylene group.
- R 5 ′ and R 6 ′ represent a lower alkoxycarbonyl group
- the ester group is reduced at the same time as the reduction of the amide bond, and a corresponding alcohol compound is obtained.
- a reduction reaction is performed in the same manner. Both are possible.
- the hydrolysis can be carried out by a known method, for example, in a solvent such as an alcoholic solvent such as methanol and ethanol, in the presence of an aqueous solution such as lithium hydroxide and sodium hydroxide, at a temperature from room temperature to a temperature at which the reaction mixture refluxes.
- the compound represented by the formula (I) —a or a salt thereof can also be produced using the compound represented by the formula (VIII) according to the following ⁇ Step 6> and Step 7>.
- Step 6> The compound represented by the formula (X) can be produced from the compound represented by the formula (VIII) according to the method of Step 5>.
- the compound represented by the formula (I) _a or a salt thereof can be produced from the compound represented by the formula (X) and the compound represented by the formula (IX).
- —Y′—Q in formula (IX) together represent an alkyl halide, aldehyde or ketone, they can be produced according to method A or B of ⁇ Step 4>, respectively.
- Y ′ —Q together represent a carboxylic acid, it can be produced by reducing according to the method of Step 5>, which bridges the amide bond formed following Method C of ⁇ Step 4>. .
- the compound represented by the formula (I) 1b or a salt thereof is obtained by reacting the compound represented by the formula (XI) and the compound represented by the formula ( ⁇ ⁇ ⁇ ⁇ ) or the compound represented by the formula (XIII) 2> It can be manufactured according to each manufacturing process. (ir)
- the compound represented by the formula (VI ′) is obtained by adding the compound represented by the formula (XI) to the compound represented by the formula (XII), and then converting the generated hydroxyl group as necessary. It can be manufactured by making When the compound represented by the formula (XI) is a compound in which W is a hydrogen atom, the addition reaction is performed by an ether-based solvent such as getyl ether 'tetrahydrofuran or a hydrocarbon-based solvent such as benzene / hexane.
- an ether-based solvent such as getyl ether 'tetrahydrofuran or a hydrocarbon-based solvent such as benzene / hexane.
- the compound represented by the formula (XI) is converted to lithium di-iso-propylamide, lithium hexamethyldisilazide, potassium hexamethyldisila.
- metal amide reagents such as zide and organometallic reagents such as tin (III) triflate to form metal enolates
- react with the compound represented by the formula (XII) at room temperature and at room temperature It can be done by doing.
- the addition reaction is carried out by an ether-based solvent such as getyl ether or tetrahydrofuran;
- a compound represented by the formula (XI) is reacted with a zinc powder in a solvent that does not participate in a reaction such as a hydrocarbon solvent to obtain a zinc compound, and then is reacted with a compound represented by the formula (XII).
- a compound represented by the formula (XII) can be performed.
- the alkylation of the tertiary hydroxyl group generated by the addition reaction is carried out at a temperature at which the reaction mixture is refluxed from 1 Ot: in a solvent not involved in the reaction such as dimethylformamide and dimethylimidazolidone in the presence of a salt group such as sodium hydride,
- the reaction can be carried out using an alkylating agent such as an alkyl halide typified by methyl iodide or an alkyl sulphate typified by dimethyl sulfate at room temperature under ice-cooling to room temperature.
- the compound represented by the formula (VI ′) can also be produced according to the following Step 2>, ⁇ Step 3>, and ⁇ Step 4>.
- Step 2> The compound represented by the formula (VI I ′) can be produced from the compound represented by the formula (XI) and the compound represented by the formula (XIII) according to the method of the step 1> it can.
- Step 3> The compound represented by the formula ( ⁇ ′) (wherein R 3 , R 4 , R 5 , R 6 and Z ′ represent the same meaning as described above) is represented by the formula (VII ′) Can be produced from the compound to be produced according to the method of ⁇ Step 3> of Preparation Method 1>.
- Step 4> The compound represented by the formula (VI ') is converted from the compound represented by the formula ( ⁇ ) and the compound represented by the formula (IX) to the method of ⁇ Step 4> of ⁇ Production method 1>. Therefore, it can be manufactured.
- ⁇ Step 5> The compound represented by the formula (I) -1b or a salt thereof is to be produced from the compound represented by the formula (VI ') according to the method of ⁇ Step 5> of ⁇ Production method 1>. There is a monkey.
- the compound represented by the formula (I) -b or a salt thereof can also be produced from the compound represented by the formula (VIII ') according to the following ⁇ Step 6> and Step 7>.
- Step 6> The compound represented by the formula (X ′) can be produced according to the method of Step 5> of the compound represented by the formula ( ⁇ ).
- the compound represented by the formula (X ') is reduced according to the method of Step 5> through the compound represented by the formula ( ⁇ ), and then deprotected at the 1-position of piperidine according to the method of ⁇ Step 3>. It can also be manufactured by carrying out.
- Step 7> The compound represented by the formula (I) 1b or a salt thereof is obtained by the ⁇ Step 7> of the production method 1> from the compound represented by the formula (X ′) and the compound represented by the formula (IX). > It can be manufactured according to the method.
- a compound represented by the formula (I) —c (wherein A, R 3 , R 4 , R 5 , R 6 , R 7 , X, Y and Z represent the same meaning as described above) or a salt thereof,
- the compound represented by the formula ( ⁇ ′) and the compound represented by the formula (XIV) or the compound represented by the formula (XV) can be produced according to each production process of the reaction formula 3>.
- Y ′ represents an alkylenecarbonyl group or a carbonyl group
- the amide bond is reduced according to the method of ⁇ Step 5> of the subsequent production method 1> to obtain the compound of the formula (I) 1c.
- the compounds represented can be prepared.
- the compound represented by the formula (I) 1c or a salt thereof can also be produced according to the following Step 2>, ⁇ Step 3>, and Step 4>.
- Step 2> The compound represented by the formula (XVI) (wherein R 3 , R 4 , R 5 , R 6 , R 7 , P and Z represent the same meaning as described above) is represented by the formula (III ′) From the compound represented by the formula (XV) and the compound represented by the formula (XV).
- ⁇ Step 4> The compound represented by the formula (I) 1c or a salt thereof is prepared from the compound represented by the formula (XVII) and the compound represented by the formula (IX) in ⁇ Step 7> of ⁇ Production method 1>. It can be manufactured according to the method of (1).
- a compound represented by the formula (I) —d (wherein A, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X and Y have the same meanings as described above) or a salt thereof Can be produced from the compound represented by the formula ( ⁇ ) and the compound represented by the formula (XVIII) or the compound represented by the formula (XIX) according to each production step of Reaction formula 4>.
- the compound represented by the formula (I) -d or a salt thereof is prepared by converting the compound represented by the formula ( ⁇ ) and the compound represented by the formula (XVIII) into methylene chloride in the presence of an acid catalyst or a base catalyst.
- '' Halogen solvents such as chloroform, getyl ether '' Ether solvents such as tetrahydrofuran, hydrocarbon solvents such as benzene and hexane, and polar solvents such as dimethylformamide and dimethyl sulfoxide
- the reaction can be carried out in a non-solvent at a temperature from 0 to the reflux temperature of the reaction mixture.
- Journa 1 of the American Chemical Society, Vol. 99, 8208—82 14 Pp. 1977 and can be produced by reacting in getyl ether at room temperature in the presence of neutral alumina.
- the compound represented by the formula (I) -d can be produced by reducing the amide bond according to the method of ⁇ Step 5> of Kikyu Production Method 1>.
- the compound represented by the formula (I) 1d or a salt thereof can also be produced according to the following ⁇ Step 2>, ⁇ Step 3>, and ⁇ Step 4>.
- Step 4> The compound represented by the formula (I) 1d or a salt thereof is prepared by the ⁇ step 7> of the production method 1> from the compound represented by the formula (XXI) and the compound represented by the formula (IX). It can be manufactured according to the following method.
- Each compound synthesized by each of the above production methods can also be converted at each stage of the production process according to the method shown below.
- R 4 represents a hydrogen atom
- alkylating agents such as alkyl halides typified by methyl iodide and alkyl sulphates typified by dimethyl sulfuric acid
- inorganic bases such as hydroxylated lime, sodium hydride, carbonic lime, triethylamine pyridine, etc.
- halogen-based solvents such as methylene chloride-chloroform
- ether-based solvents such as dimethyl ether and tetrahydrofuran
- hydrocarbon-based solvents such as benzene and hexane
- dimethylformamide and dimethyl sulfoxide By reacting in a solvent such as a polar solvent that does not participate in the reaction at a temperature at which the reaction mixture refluxes from 0, it can be converted into a compound in which R 4 is a lower alkyl group.
- the reaction may be carried out using an aldehyde derivative or a ketone derivative according to Method B described in ⁇ Production Method 1>, Step 4>.
- R 4 can be converted to a compound in which R 4 is a lower alkyl group. Further, by performing acylation using a carboxylic acid derivative according to the method described in ⁇ Production method 1>, Step 1>, R 4 can be converted to a compound in which R 4 is a lower alkenyl group. At this time, the compound can be converted to a compound in which R 4 is a lower alkyl group by performing a reduction operation in ⁇ Step 5> of ⁇ Production Method 1>.
- R 4 ′ is a hydrogen atom
- those in which R 4 ′ is a hydrogen atom include halogens represented by methyl iodide.
- Halogen solvents such as methylene chloride and chloroform, using an alkylating agent such as alkyl sulfate represented by alkyl chloride and dimethyl sulfate in the presence of base such as potassium hydroxide and sodium hydride Ethers:
- solvents that do not participate in the reaction such as ether solvents such as tetrahydrofuran, hydrocarbon solvents such as benzene and hexane, and polar solvents such as dimethylformamide and dimethyl sulfoxide.
- ether solvents such as tetrahydrofuran
- hydrocarbon solvents such as benzene and hexane
- polar solvents such as dimethylformamide and dimethyl sulfoxide.
- those having an alkoxy group as a substituent on the benzene ring can be dealkylated using boron tribromide or hydrobromic acid monoacetic acid.
- the temperature at which the reaction mixture is refluxed from —2O : preferably from ice-cooled to room temperature
- a base such as sodium hydride
- alkylation using the above-mentioned alkylating agent can lead to other alkoxy-substituted products.
- alkylation is performed using an alkylating agent such as halogenated alkyl having an oxygen functional group typified by bromoacetate ester or bromoacetone, followed by lithium aluminum hydride, sodium borohydride, or the like.
- an alkylating agent such as halogenated alkyl having an oxygen functional group typified by bromoacetate ester or bromoacetone, followed by lithium aluminum hydride, sodium borohydride, or the like.
- a reducing agent such as sodium borohydride is used, and a solvent such as an alcohol-based solvent such as methanol and ethanol is used.
- a solvent such as an alcohol-based solvent such as methanol and ethanol is used.
- each of the compounds produced by the above methods has a lower alkoxy carboxy group as a substituent
- a known method such as methanol and ethanol is used.
- Can be converted to a carboxyl group by hydrolysis at room temperature to a temperature at which the reaction mixture refluxes in the presence of an alkaline aqueous solution such as lithium hydroxide and sodium hydroxide in an alcoholic solvent such as
- an alkaline aqueous solution such as lithium hydroxide and sodium hydroxide in an alcoholic solvent
- the compound can be converted into a rubamoyl group which may be mono- or di-substituted by a lower alkyl group.
- each of the compounds produced by the above methods has a halogen atom, preferably a bromine atom as a substituent on the aromatic ring
- a known method such as copper (I) cyanide, potassium cyanide, etc.
- Reaction mixture from room temperature in a solvent that does not participate in reactions such as polar aprotic solvents such as dimethylformamide, dimethylsulfoxide, and dimethylimidazolidone.
- a bromine atom By reacting at a temperature at which 3 is refluxed, a bromine atom can be converted to a cyano group.
- a transition metal complex such as a palladium complex represented by palladium acetate ⁇ a nickel complex represented by tetrakistriphenylphosphine nigel can be used as a catalyst.
- the cyano group is further reacted with an organometallic compound such as alkylmagnesium bromide or alkyllithium in a solvent that does not participate in the reaction, such as ether solvents such as getyl ether 'tetrahydrofuran, and the like at room temperature for 1 to 100 hours.
- an organometallic compound such as alkylmagnesium bromide or alkyllithium in a solvent that does not participate in the reaction, such as ether solvents such as getyl ether 'tetrahydrofuran, and the like at room temperature for 1 to 100 hours.
- each compound synthesized by each of the above-mentioned production methods has a reactive group such as a hydroxyl group, an amino group, or a hydroxyl group as a substituent
- these groups are appropriately protected in each production step, and at an appropriate stage.
- the protecting group can also be removed.
- the method of introducing and removing such a protecting group may be appropriately determined depending on the type of the group to be protected or the type of the protecting group.
- the above-mentioned Protective Grooves 'In' Organic Synthesis This can be done by the method described in the 3rd edition, 1999 review.
- the compound represented by the formula (XII) can be produced according to a known method.
- it can be produced by reacting 4-piperidone or an equivalent thereof with a compound represented by the formula (IX) according to the method described in ⁇ Step 4> of Production method 1>.
- the compound represented by the formula (IV) and the formula (V) can be prepared by a method of preparing a compound represented by the formula (XII) or the formula (XIII) and acetic acid having a desired substituent or its protected form 2) Can be produced by reacting according to the method described in (1).
- Rats were anesthetized with pentobarbitil sodium 4 OmgZkg (p.), Fixed in a supine position, and then heparin was administered through the jugular vein. Artificial respiration was started under the conditions of 20 mLZkg and 54 strokes, and the chest was opened between the second and third ribs. Aortic or al, ImMC a C 1 K rebs -R inger- HEPES solution containing 2 (KRH), PH7. 4 inserted in the retrograde polyethylene tubing filled with fixed, simultaneously perfused with 70 cm water column pressure heart was extracted.
- the heart was beaten by perfusion with KRH (Ca 2+ — free KRH) containing no Ca ”for 10 minutes. also oxygenated with 95% 0 2/5 CO 2 mixed gas was used after being maintained at at 37. then 2 5 MC a C 1 2, the KRH containing 0.06% collagenase and 0.1% albumin .
- the heart was perfused 2 0 min at approximately 3 7 until write soft ventricular portion 3 7 X: after shredding in the collagenase solution, approximately with aeration at 95% ⁇ 2 Z5% C_ ⁇ 2 Enzyme treatment was continued for 10 minutes
- the cells were dispersed by pipetting, filtered through a stainless mesh to remove connective tissue, etc.
- Albumin was added to the filtrate to stop the enzyme reaction, and then centrifuged to remove the supernatant.
- Cells were washed with 25 ⁇ MC a C 1 and 1% albumin.
- the test compound was administered to rats that had fasted from the previous day at a dose of 1 OmL / kg using an oral probe while awake. 35 minutes after administration, the mice were anesthetized with pentobarbital sodium 6 Om / kg (ip), fixed in a supine position on a heat insulating sheet, and kept at about 37 during the experiment. Artificial respiration was started under the conditions of 15 mLZkg and 55 strokes minutes. Approximately 2 cm of a polyethylene tube filled with heparin-saline solution for blood pressure measurement was inserted from the left common aortic artery and fixed. The left chest was further opened, and the left main coronary artery was sewn with a suture needle to the left atrial side for coronary artery ligation.
- Coronary ligation was performed for 5 minutes, followed by reperfusion for 10 minutes.
- Coronary ligation was performed by passing a suture through a polyethylene tube snare, pulling both ends of the thread, and pressing the snare against the heart, and reperfusion was performed by removing the snare.
- Aortic pressure was measured using a pressure transducer.
- Electrocardiograms were derived by standard limb lead II. Heart rate was measured from the R-R interval on the electrocardiogram or the blood pressure using an evening meter. Each measured value was recorded on a chart paper using a recorder while checking it on a monitor, and simultaneously on a magnetic medium using a personal computer.
- the compound of the present invention suppressed the incidence of ventricular fibrillation (%).
- Beagle dogs were anesthetized with 3% Omg Z kg (v.) Of Choppen sodium and then ventilated with a respirator at 2 Om LZ kg, 22 times / min.
- the left fifth intercostal space was opened, the pericardium was incised, and the heart was suspended in the thoracic cavity.
- the anterior descending coronary artery of the left coronary artery was peeled about 1 cm downstream from the bifurcation with the rotation technique.
- a stenosis was created by withdrawing the injection needle (single-stage ligation). Thirty minutes later, it was completely ligated with another suture (two-stage ligature).
- a bipolar electrode was sutured to the left atrial appendage for recording atrial potential, a catheter filled with heparin solution for the left common artery for blood pressure measurement and blood collection, and a left outer nod for administration of the test compound.
- a catheter was inserted into the vein. All of these catheter and electrode leads were routed under the skin to the nod back.
- the antibiotic animal mycilidizol
- the chest was closed and returned to the rearing cage. Twenty-four hours after the operation, the dog was hung without anesthesia on a hammock on a fixation table. After stabilization, the test compound was administered at a rate of 1 O mg Z kg Z hours. Aortic pressure was measured using a pressure transducer.
- the electrocardiogram (standard limb lead II) and atrial potential were derived using a bioelectric amplifier. Heart rate was measured from the R-R interval on the electrocardiogram or blood pressure. Each measured value was recorded on a chart paper using a recorder while confirming it on a monitor, and simultaneously on a magnetic medium using a personal computer. An arrhythmia ratio represented by [extra systolic number Z (extra systolic number + sinus rhythm)] X 100 during one minute was used as an index of arrhythmia occurrence frequency. Table 3 shows the results. Table 3 Efficacy of Example Compound 146 in a Canine Coronary Artery Ligated Arrhythmia Model
- the compound of the present invention suppressed the occurrence of extra-systole.
- Example 1 Females of 6-week-old Crj: (SD) IGS rats were orally gavaged once daily with the compounds of Example Nos. 146, 233 and 278 for 14 days.
- Example 1 Females of 6-week-old Crj: (SD) IGS rats were orally gavaged once daily with the compounds of Example Nos. 146, 233 and 278 for 14 days.
- Example 1
- the compound of 46 is a dose of 1 O Omg / kg gZd ay or less, and the compound of Example 233 is
- the compound of the present invention suppressed contracture of isolated cardiomyocytes by veratrin.
- the compound of the present invention suppressed the occurrence of ventricular fibrillation, which is a serious arrhythmia, in the rat ischemia-reperfusion arrhythmia model, and reduced mortality.
- the compound of the present invention hardly affected the electrocardiogram PQ interval or QRS width. No abnormalities were observed in the toxicity test, indicating that the compound of the present invention has low toxicity. It has been shown.
- the compound of the present invention is effective in an animal arrhythmia model and has little effect on the electrocardiogram of a normal animal, and thus is useful as a drug having no proarrhythmic action for the treatment or prevention of arrhythmia.
- Arrhythmia is a general term for abnormal rhythm function among cardiac functions, and occurs when abnormal heart conduction or abnormal conduction occurs.
- Arrhythmias include ventricular arrhythmias and atrial (supraventricular) arrhythmias, both of which are encompassed by the present invention. More specifically, arrhythmias include supraventricular premature beats, ventricular premature beats, supraventricular tachycardia, WPW syndrome, atrial flutter / atrial fibrillation, ventricular tachycardia, and ventricular fibrillation.
- ventricular arrhythmias ventricular tachycardia and ventricular fibrillation are considered serious arrhythmias, and have been suggested to cause sudden death, especially in patients with ischemic heart disease such as patients with myocardial infarction and heart failure . Most sudden deaths occur in those with some form of heart disease, but there is no underlying disease, but overwork can cause fatal arrhythmias and sudden death.
- the pharmaceutical composition of the present invention does not affect the electrical activity of normal myocardium and has no proarrhythmic effect, it treats or prevents, or suddenly treats ventricular tachycardia, which is a serious arrhythmia, ventricular fibrillation. Particularly useful in preventing death.
- Atrial flutter / atrial fibrillation itself causes electrical remodeling and is susceptible to atrial flutter / atrial fibrillation.
- No clinical application of drugs that suppress electrical remodeling has yet been undertaken, suggesting that excessive sodium and calcium influx could be attributed to this phenomenon.
- Veratrin suppresses the inactivation of sodium channels in cardiomyocytes and generates a sustained sodium current, which increases intracellular sodium concentration, and subsequently via the sodium Z calcium exchange transport system. Since the increase in the intracellular calcium concentration causes contracture, the compound of the present invention is considered to suppress the sustained Na current. From these facts, suppression of excessive sodium influx by the sustained sodium current-suppressing action of the compound of the present invention is also useful for preventing progression of atrial flutter / atrial fibrillation.
- the compound of the present invention has an effect of suppressing contracture of isolated cardiomyocytes by veratrine, Suppresses sustained sodium current, resulting in heart failure, angina, myocardial infarction, cardiovascular disorders associated with revascularization by PTC AZPTCRZCABG, etc., myocardial ischemia-reperfusion injury (excluding severe arrhythmias), acute cerebral infarction , Cerebral hemorrhage, transient cerebral ischemia, subarachnoid hemorrhage, head trauma, sequelae of cerebral surgery, cerebrovascular accidents such as sequelae of cerebral arteriosclerosis, transplant organ damage at the time of organ transplant, temporary blood flow of organ at the time of surgery Symptoms based on blockade, or treatment of convulsions, epilepsy, dementia (cerebrovascular, senile), neuralgia, migraine, neuropathic pain, digitalis poisoning, avian poisoning, pyrethroid pesticide poisoning, etc.
- the compound of the present invention may be caused by abnormal channel inactivation due to sodium channel gene abnormality, that is, hyperkal emicperiod icparalysis which is a congenital disease caused by generation of persistent sodium current, and congenital abnormal muscle. It can also be used for tension, long QT syndrome, etc.
- the medicament of the present invention is administered in the form of a pharmaceutical composition.
- the pharmaceutical composition of the present invention may contain at least one or more of the compounds represented by the formula (I) of the present invention, and is prepared in combination with a pharmaceutically acceptable additive.
- excipients eg, lactose, sucrose, mannitol, microcrystalline cellulose, caffeic acid
- binders eg, microcrystalline cellulose, sugars (mannitol, sucrose, sorbitol, erythritol, xylitol), dextrin , Hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), macrogol
- lubricant eg, magnesium stearate, calcium stearate, talc
- coloring agent eg, flavoring agent
- Disintegrants eg, corn starch, carboxymethylcellulose
- preservatives benzalkonium chloride, paraoxybenzoate
- tonicity agents eg, glycerin, sodium chloride
- Such dosage forms include tablets, capsules, granules, powders, suppositories, vaginal suppositories, sublingual agents, buccals, disintegrating agents in the oral cavity, chewing agents, lozenges, jellies, pastes, oral cavity Mucosal patches, syrups (oral solutions, emulsifiers), inhalants, injections, nasal formulations (solutions, powders), external preparations (ointments, creams, jellies, gels) Patches (tapes) Agents, patches, cataplasms, etc.), liquids, suspending agents, sprays, etc., orally or parenterally (eg, intravenous, intraarterial, subcutaneous, intramuscular, rectal) , Vaginal administration, intranasal administration or transmucosal absorption of oral mucosa, penile mucosa and the like).
- parenterally eg, intravenous, intraarterial, subcutaneous, intramuscular, rectal
- the dose of the present invention is usually 0.1 mg to 2.5 g, preferably 0.5 mg to 1.0 g, more preferably 1 mg to 50 mg per day per adult, depending on the symptom or administration route. Can be increased or decreased as appropriate.
- Nuclear magnetic resonance spectrum is JEOL J NM-EX 270 (J EOL J NM-EX 270) FT-NMR (* is displayed overnight) manufactured by JEOL Ltd. or JEOL J NM-LA 300 (JE ⁇ LJ NM_LA300) FT-NMR (manufactured by Nippon Electronics Co., Ltd.) and infrared absorption spectrum (IR) of HORIBA (HOR IBA) FT-200 or FT-720 (both manufactured by HORIBA, Ltd.) ) was measured using a Mettler FP 80 or FP 90 (both manufactured by Mettler Co., Ltd.). (Example 1)
- a borane-methyl sulfide complex salt solution (10 M; 13.5 mL) was added to a solution of the compound (10 g) obtained in Step 1 in anhydrous tetrahydrofuran (15 OmL), and the mixture was heated under reflux for 2 hours. After cooling, methanol (10 mL) and a 10% hydrochloric acid-methanol solution (1 OmL) were added, and the mixture was heated under reflux for 2 hours. After allowing to cool, the solvent was distilled off under reduced pressure, water and saturated aqueous sodium hydrogen carbonate were added to make the mixture alkaline, and the mixture was extracted with ethyl acetate.
- Step 1 >-(4-cyclohexyloxyphenyl) -N-methyl-2- (1-benzyl-4 -hydroxypiperidine-14-yl) acetamide
- Step 2 > 1 Benzyl 4-[2 -[N- (4-cyclohexyloxyphenyl) -N-methylamino] ethyl] piperidine-4-ol
- Step 2 Synthesis of 1-benzyl-4- [2- [N- (4-n-butoxyphenyl) -1-N-methylamino] —1-hydroxyethyl] piperidin-4-ol Obtained in Step 1 Using the compound (0.70 g), desilylation was simultaneously performed by treatment with hydrochloric acid in the same manner as in Step 2 of Example 1 to obtain the title compound (0.48 g).
- Step 2> 4- [2— [N- (4-n-butoxyphenyl) -1-N-methylamino] ethyl] 1-1-1 [2- (3,4-methylenedioxyphenyl) ethyl] piperidine— 4 one oar
- Step 1 N- (4-n-butoxyphenyl) —N-methyl—2— [4-hydroxy-11- (phenoxyacetyl) piperidine—41-yl] acetamide
- Step 2 4— [2- [N- (4-n-butoxyphenyl) —N-methylamino] ethyl] 1- (2-phenoxicetyl) piperidine
- Step 2 Synthesis of 4 -— [2 -— [N- (4-n-butoxyphenyl) —N-methylamino] ethyl] —1- (2-phenylethyl) piperidin-1-ol Obtained in Step 1
- the title compound (0.38 g) was obtained in the same manner as in Step 2 of Example 1 using the compound (0.62 g).
- Step 3 Synthesis of 4 -— [2- [N- (4-n-butoxyphenyl) amino] ethyl] — 1— [2- (4-fluorophenyl) ethyl] piperidin-4-ol Obtained in Step 2
- the title compound (0.49 g) was obtained in the same manner as in Step 2 of Example 1 using the obtained compound (0.60 g).
- Step 3 Synthesis of N- (4-cyclobutoxyphenyl) -N-methyl-2- [4-hydroxy-1- (phenylacetyl) piperidine-4-yl] acetamide
- the title compound (0.43 g) was obtained in the same manner as in Step 1 of Example 44, using the compound (0.35 g) obtained in Step 2.
- Step 4 Synthesis of 4- [2- [N- (4-cyclobutoxyphenyl) -N-methylamino] ethyl] -1- (2-phenylethyl) piperidine-4-1-ol Obtained in Step 3
- the title compound (0.35 g) was obtained in the same manner as in Step 2 of Example 1 using the compound (0.40 g).
- Step 1 Synthesis of N- (4-n-butoxy-3-methoxycarbonylphenyl) -N-methyl-2- (1-benzyl-4-hydroxypiperidine-4-yl) acetamide
- the title compound (0.88 g) was obtained in the same manner as in Step 1 of Example 19 using the compound (1.18 g).
- Step 3 To a solution of the compound obtained in Step 3 (1.23 g) in methanol (7 mL) was added an aqueous solution (2.7 mL) of lithium hydroxide monohydrate (0.20 g), and the mixture was heated for 10 minutes. Refluxed. After cooling, the solvent was distilled off under reduced pressure. Water was added to the residue, and the residue was washed with ethyl acetate. The aqueous layer was adjusted to pH 3 with 1 N hydrochloric acid, and extracted with methylene chloride. Organic layer After washing with water and saturated saline and drying over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure to obtain the title compound (1.19 g).
- Trifluoroacetic acid (5 mL) was cooled on ice, anisol (1.5 mL) and the compound obtained in Step 1 (1.6 g) were added, and the mixture was stirred at room temperature for 2 hours.
- the reaction solution was concentrated under reduced pressure, ether was added to the residue, and the mixture was extracted with a 1N aqueous sodium hydroxide solution.
- the aqueous layer was adjusted to pH 2 by adding concentrated hydrochloric acid, and extracted with methylene chloride.
- the organic layer was washed with brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was recrystallized from ether to give the title compound (1.25 g).
- Trifluoroacetic acid (3 mL) was cooled with ice, the compound (0.80 g) obtained in Step 2 was added, and the mixture was stirred for 30 minutes.
- the reaction solution was concentrated under reduced pressure, a 1 N aqueous solution of sodium hydroxide was added to the residue, and the mixture was extracted with ethyl acetate. Dry the organic layer with anhydrous sodium sulfate Thereafter, the solvent was distilled off under reduced pressure.
- Step 5 Synthesis of 1-benzyl-4-methoxy-4- [2- [N- (4-n-butoxyphenyl) -N-methylamino] ethyl] piperidine
- Step 1 ⁇ —Methyl— ⁇ — [4- (2-Methyl-2-butoxy) phenyl] —2 -— (1-benzyl-4-hydroxypiperidine-1.4-d) acetamide
- Step 2 1-Benzyl—4 — [2- [N-Methyl-N— [4 -— (2-methyl-2-butoxy) phenyl] amino] ethyl] piperidine—4-ol
- Step 1 N- (4-n-butoxyphenyl) -N-iso-propyl-2- (1-benzyl-14-hydroxypiperidine-14-yl) acetamide
- Step 2 1-benzyl-4 — [2 -— [N- (4-n-butoxyphenyl) -N-iso—propylamino] ethyl] piperidine— 4-all
- Example 7 To a solution of the compound (0.29 g) obtained in Step 1 of 2 in dimethylformamide (5 mL) was added 2-phenoxexetyl bromide (0.2 g), potassium carbonate (0.14 g) and iodine. Sodium chloride (15 mg) was added and the mixture was stirred at 100 for 2 hours. The reaction solution was poured into ice water and extracted with ethyl acetate. The organic layer was washed with water and extracted with 1N hydrochloric acid. The aqueous layer was adjusted to pH 9 with sodium bicarbonate and extracted with ethyl acetate.
- Step 3 Synthesis of 4- [2- [N-methyl-N- (4-iso-propoxyphenyl) amino] — 1-hydroxyethyl] piperidin-4-ol Compound obtained in Step 2
- the title compound (0.5 g) was obtained in the same manner as in Step 2 of Example 122 using (0.7 g).
- Example 84 The compound (0.35 g) obtained in Example 84 was dissolved in acetic acid (4 mL), iron powder (0.15 g) was added, and the mixture was stirred at 70 to 80 for 1.5 hours. Insolubles were removed by filtration, and the filtrate was concentrated under reduced pressure. The obtained residue was dissolved in methylene chloride, and washed sequentially with saturated aqueous sodium hydrogen carbonate and saturated saline. After the organic layer was dried over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure.
- Example 86 The compound (0.44 g) obtained in Example 86 was dissolved in methanol (20 mL), an aqueous solution (2 mL) of lithium hydroxide monohydrate (42 mg) was added, and the mixture was heated under reflux for 18 hours. The solvent was distilled off under reduced pressure, ether was added to the obtained residue, and the precipitated solid was filtered to obtain the title compound (0.35 g).
- Example 25 4- [2— [N-methyl-1-N— (4-iso_propoxyphenyl) amino] ethyl] 111- (3-nitrophenylmethyl) piperidin-1-ol dihydrochloride (Example 252) )
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36760/00A AU3676000A (en) | 1999-04-09 | 2000-04-10 | 4-hydroxypiperidine derivatives having antiarrhythmic effect |
CA002369691A CA2369691A1 (en) | 1999-04-09 | 2000-04-10 | 4-hydroxypiperidine derivatives having antiarrhythmic effect |
EP00915467A EP1182192A4 (en) | 1999-04-09 | 2000-04-10 | 4-HYDROXYPIPERIDINE DERIVATIVES WITH ANTI-ARRHYTHMIC EFFECT |
US09/969,639 US6710060B2 (en) | 1999-04-09 | 2001-10-04 | 4-hydroxypiperidine derivatives having antiarrhythmic activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/103212 | 1999-04-09 | ||
JP10321299 | 1999-04-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/969,639 Continuation-In-Part US6710060B2 (en) | 1999-04-09 | 2001-10-04 | 4-hydroxypiperidine derivatives having antiarrhythmic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000061557A1 true WO2000061557A1 (fr) | 2000-10-19 |
Family
ID=14348210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/002331 WO2000061557A1 (fr) | 1999-04-09 | 2000-04-10 | Derives de 4-hydroxypiperidine ayant un effet anti-arythmique |
Country Status (5)
Country | Link |
---|---|
US (1) | US6710060B2 (ja) |
EP (1) | EP1182192A4 (ja) |
AU (1) | AU3676000A (ja) |
CA (1) | CA2369691A1 (ja) |
WO (1) | WO2000061557A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030900A1 (fr) * | 2000-10-06 | 2002-04-18 | Mochida Pharmaceutical Co., Ltd. | Sel non-deliquescent d'un derive de 4-hydroxypiperidine |
WO2004048326A1 (ja) * | 2002-11-25 | 2004-06-10 | Mochida Pharmaceutical Co., Ltd. | 4−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤 |
WO2010080864A1 (en) | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050102652A1 (en) * | 2003-11-07 | 2005-05-12 | Sony Corporation | System and method for building software suite |
WO2005062975A2 (en) * | 2003-12-23 | 2005-07-14 | Digital Networks North America, Inc. | Method and apparatus for distributing media in a pay per play architecture with remote playback within an enterprise |
EP1924326B1 (en) | 2005-08-25 | 2016-10-12 | Steven Michael Weiss | Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow |
WO2008042926A1 (en) * | 2006-10-04 | 2008-04-10 | Bristol-Myers Squibb Company | Cyclic modulators of chemokine receptor activity |
AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
WO2012118782A1 (en) | 2011-02-28 | 2012-09-07 | Repligen Corporation | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10029988B2 (en) | 2013-03-15 | 2018-07-24 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4248877A (en) * | 1973-06-22 | 1981-02-03 | Sandoz Ltd. | Organic compounds |
EP0867183A1 (en) * | 1996-07-22 | 1998-09-30 | Suntory Limited | Arylpiperidinol and arylpiperidine derivatives and drugs containing the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3350403A (en) * | 1964-04-07 | 1967-10-31 | Aldrich Chem Co Inc | Nu-phenyl amides of 4-phenyl-4-hydroxypiperidino alkyl acids |
CH587812A5 (ja) | 1973-06-22 | 1977-05-13 | Sandoz Ag | |
US4178377A (en) | 1973-06-22 | 1979-12-11 | Sandoz Ltd. | (4-Hydroxy-4-piperidyl)-alkanoic acid amides |
US3998834A (en) * | 1975-03-14 | 1976-12-21 | Janssen Pharmaceutica N.V. | N-(4-piperidinyl)-n-phenylamides and -carbamates |
US4508724A (en) * | 1984-02-03 | 1985-04-02 | A. H. Robins Company, Inc. | Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity |
-
2000
- 2000-04-10 CA CA002369691A patent/CA2369691A1/en not_active Abandoned
- 2000-04-10 EP EP00915467A patent/EP1182192A4/en not_active Withdrawn
- 2000-04-10 AU AU36760/00A patent/AU3676000A/en not_active Abandoned
- 2000-04-10 WO PCT/JP2000/002331 patent/WO2000061557A1/ja not_active Application Discontinuation
-
2001
- 2001-10-04 US US09/969,639 patent/US6710060B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4248877A (en) * | 1973-06-22 | 1981-02-03 | Sandoz Ltd. | Organic compounds |
EP0867183A1 (en) * | 1996-07-22 | 1998-09-30 | Suntory Limited | Arylpiperidinol and arylpiperidine derivatives and drugs containing the same |
Non-Patent Citations (2)
Title |
---|
HUEGI B.S. ET AL.: "Synthesis and pharmacological studies of 4,4-disubstituted piperidines: A new class of compounds with potent analgetic properties", J. MED. CHEM.,, vol. 26, no. 1, 1983, pages 42 - 50, XP002929094 * |
See also references of EP1182192A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030900A1 (fr) * | 2000-10-06 | 2002-04-18 | Mochida Pharmaceutical Co., Ltd. | Sel non-deliquescent d'un derive de 4-hydroxypiperidine |
WO2004048326A1 (ja) * | 2002-11-25 | 2004-06-10 | Mochida Pharmaceutical Co., Ltd. | 4−ヒドロキシピペリジン誘導体を有効成分とする呼吸器疾患治療剤 |
US7494987B2 (en) | 2002-11-25 | 2009-02-24 | Mochida Pharmaceutical Co., Ltd. | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient |
WO2010080864A1 (en) | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
US8809538B2 (en) | 2009-01-12 | 2014-08-19 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof |
Also Published As
Publication number | Publication date |
---|---|
AU3676000A (en) | 2000-11-14 |
US6710060B2 (en) | 2004-03-23 |
CA2369691A1 (en) | 2000-10-19 |
EP1182192A1 (en) | 2002-02-27 |
EP1182192A4 (en) | 2002-06-05 |
US20020188006A1 (en) | 2002-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104024251B (zh) | 苯磺酰胺化合物及其作为治疗剂的用途 | |
US6727264B1 (en) | Substituted anilinic piperidines as MCH selective antagonists | |
KR101352709B1 (ko) | 1위 치환 테트라히드로이소퀴놀린 화합물 | |
WO2003004027A1 (en) | Substituted anilinic piperidines as mch selective antagonists | |
WO2000061557A1 (fr) | Derives de 4-hydroxypiperidine ayant un effet anti-arythmique | |
WO1996033973A1 (fr) | Derives disubstitues en position 1,4 de piperidine | |
JP2007517846A (ja) | Gcs阻害剤としてのピペリジン誘導体 | |
WO2007017092A1 (en) | Substituted 4-benzyloxy-benzoic acid amide derivatives | |
US6642257B2 (en) | Agents for treating neuropathic pain | |
DE102006033114A1 (de) | Spirocyclische Azaindol-Derivate | |
KR20070007196A (ko) | 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법 | |
US5491152A (en) | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis | |
EP0683166A1 (de) | 3-Indolylpiperidine | |
EP2687531A1 (en) | Tetrahydrocarboline derivative | |
MXPA02010573A (es) | 4-bencil-1-(2-(4-hidroxi-fenoxi)-etil)-piperidin-3,4-diol. | |
FI107607B (fi) | Menetelmä terapeuttisesti käyttökelpoisen 1,4-piperidiinijohdannaisen valmistamiseksi | |
AU2010359835A1 (en) | Hydroxamate-based inhibitors of deacetylases | |
JP2000505461A (ja) | 胃運動機能調整特性を有する新規n―置換4―((4’―アミノベンゾイル)オキシメチル)ピペリジン類 | |
US20090275628A1 (en) | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments | |
JP2006515618A (ja) | 置換アルキルアミドピペリジン類 | |
WO2001070687A1 (de) | Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können | |
WO2006121104A1 (ja) | ピペリジン環を有するインドール誘導体の結晶およびその製法 | |
MXPA06004038A (es) | Compuestos de 1-'2-(4-hidroxifenil)-2-hidroxietil-piperidin-4-ol como antagonsitas del receptor n-metil-d-aspartato. | |
US20040186103A1 (en) | Substituted alkyl amido piperidines | |
KR20040015734A (ko) | 4-[4-[4-(히드록실디페닐메틸)-1-피페리디닐]-1-히드록시부틸]-α,α-디메틸벤젠 아세트산 및 그 염산염의 신규 결정형태 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 610832 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09969639 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2369691 Country of ref document: CA Ref country code: CA Ref document number: 2369691 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000915467 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000915467 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000915467 Country of ref document: EP |